Bicara Therapeutics Inc. Common Stock (BCAX) vs GoodRx Holdings, Inc. (GDRX)
A side-by-side comparison of Bicara Therapeutics Inc. Common Stock and GoodRx Holdings, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
BCAX
Bicara Therapeutics Inc. Common Stock
$17.29HealthcareDelayed quote: Oct 5, 2026, 4:00 PM EDT
GDRX
GoodRx Holdings, Inc.
$3.36HealthcareDelayed quote: Oct 5, 2026, 4:00 PM EDT
Total return — BCAX vs GDRX
growth of $100 · dividends reinvested · last 2yBCAX -26.1% (-14.1%/yr)GDRX -56.5% (-34.0%/yr)BCAX compounded faster over this window
BCAX GDRX
BCAX vs GDRX: by the numbers
- •GDRX is the larger company ($1.16B vs $1.14B market cap).
- •GDRX is profitable (2.07% net margin) while BCAX runs a net loss (0.00%).
Metrics side by side
Valuation
| Metric | BCAX | GDRX |
|---|---|---|
| P/E ratio | N/A | 79.06 |
| P/S ratio | N/A | 1.48 |
| P/B ratio | 2.42 | 1.80 |
| EV / EBITDA | N/A | 8.32 |
| FCF yield | N/A | 12.51% |
Profitability
| Metric | BCAX | GDRX |
|---|---|---|
| Gross margin | 0.00% | 88.05% |
| Operating margin | 0.00% | 10.25% |
| Net margin | 0.00% | 2.07% |
| ROE | -39.54% | 2.51% |
| ROIC | -42.98% | 3.72% |
Growth (annualized)
| Metric | BCAX | GDRX |
|---|---|---|
| Revenue CAGR (5Y) | N/A | 4.47% |
| FCF CAGR (5Y) | N/A | 11.72% |
| Total return CAGR (5Y) | N/A | -39.98% |
Frequently asked
- Is BCAX or GDRX more profitable?
- GDRX runs the higher net margin — BCAX at 0.00% versus GDRX at 2.07%.
Go deeper
Dig into the metrics
GoodRx P/E ratioBicara Therapeutics Inc. Common Stock ROEGoodRx ROEBicara Therapeutics Inc. Common Stock operating marginGoodRx operating marginBicara Therapeutics Inc. Common Stock revenue growthGoodRx revenue growthBicara Therapeutics Inc. Common Stock free cash flowGoodRx free cash flow
Bicara Therapeutics Inc. Common Stock & GoodRx appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.